Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02264860 · ClinicalTrials.gov registry record · NA
Researching Alveolar Macrophage Improvements With Supplements in HIV
A NA study, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 67
- Enrollment target
NCT02264860: Completed NA study, sponsored by Emory University.
NCT02264860 is a NA study that has completed, run by Emory University. The registered enrollment target is 67 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02264860, a NA study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 67 participants
- Enrollment target
Study Summary
HIV infection causes systemic zinc deficiency and oxidative stress that impairs host immunity in the alveolar space.The purpose of this study is to see if taking two nutritional supplements, zinc and SAMe (S-adenosylmethionine), can improve lung health and immune function in persons with HIV. The investigators hypothesize that long-term dietary supplementation with zinc and the glutathione precursor SAMe will enhance pulmonary host immune function in HIV-infected individuals who do not respond adequately to ART alone.
Primary Outcome
Incidence of treatment-related adverse events, particularly gastrointestinal problems such as nausea, gastritis or diarrhea
Interventions
- DIETARY_SUPPLEMENT Zinc and SAMe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2014-10 |
| Est. Completion | 2018-12-15 |
| Phase | NA |
What the finished NCT02264860 record still lists
NCT02264860 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Zinc and SAMe is the first listed.
NCT02264860 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02264860 about?
NCT02264860 is a clinical study titled "Researching Alveolar Macrophage Improvements With Supplements in HIV". HIV infection causes systemic zinc deficiency and oxidative stress that impairs host immunity in the alveolar space.The purpose of this study is to see if taking two nutritional supplements, zinc and SAMe (S-adenosylmethionine), can improve lung health and immune function in persons with HIV. The i...
What is the current status of trial NCT02264860?
This trial is currently completed. It is a NA study. The enrollment target is 67 participants. The study started on 2014-10. Estimated completion is 2018-12-15.
What interventions are being tested in trial NCT02264860?
The interventions under investigation include: Zinc and SAMe (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02264860?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02264860's enrollment target sits among peer trials
67 1139th of 2000 higher than 862 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia